Skip to main content

Table 1 Relapse rate, in absence of treatment

From: Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

 

EDSS 1

EDSS 2

EDSS 3

EDSS 4

EDSS 5

EDSS6

EDSS 7

EDSS 8–10

Relapse rate prior to switch/escalation, RRMS (# events/year)

1.7534 [6]

1.7534 [6]

1.6698 [6]

1.7966 [6]

1.3793 [6]

1.5556 [6]

1.5556 [6]

0.1555 [25,26,27]

Relapse rate, SPMS (# events/year)

10.0000 [25,26,27]

0.3147 [25,26,27]

0.6020 [25,26,27]

0.5146 [25,26,27]

0.1604 [25,26,27]

0.1387 [25,26,27]

0.1041 [25,26,27]

0.1041 [25,26,27]

Patient distribution at model baseline (%)

25.61% [6]

37.19% [6]

20.70% [6]

10.18% [6]

6.32% [6]

0.00% [6]

0.00% [6]

0.00% [6]

  1. EDSS expanded disability status scale, RRMS relapsing-remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis